These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

541 related articles for article (PubMed ID: 27324313)

  • 1. Immunological Aspects of Malignant Gliomas.
    Cohen-Inbar O; Zaaroor M
    Can J Neurol Sci; 2016 Jul; 43(4):494-502. PubMed ID: 27324313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current challenges in designing GBM trials for immunotherapy.
    Weathers SP; Gilbert MR
    J Neurooncol; 2015 Jul; 123(3):331-7. PubMed ID: 25577401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advances in Experimental Targeted Therapy and Immunotherapy for Patients with Glioblastoma Multiforme.
    Polivka J; Polivka J; Holubec L; Kubikova T; Priban V; Hes O; Pivovarcikova K; Treskova I
    Anticancer Res; 2017 Jan; 37(1):21-33. PubMed ID: 28011470
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Advances in Immunotherapy for Glioblastoma Multiforme.
    Huang B; Zhang H; Gu L; Ye B; Jian Z; Stary C; Xiong X
    J Immunol Res; 2017; 2017():3597613. PubMed ID: 28299344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Emerging immunotherapies for glioblastoma.
    Desai R; Suryadevara CM; Batich KA; Farber SH; Sanchez-Perez L; Sampson JH
    Expert Opin Emerg Drugs; 2016 Jun; 21(2):133-45. PubMed ID: 27223671
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The Safety of available immunotherapy for the treatment of glioblastoma.
    Farber SH; Elsamadicy AA; Atik AF; Suryadevara CM; Chongsathidkiet P; Fecci PE; Sampson JH
    Expert Opin Drug Saf; 2017 Mar; 16(3):277-287. PubMed ID: 27989218
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in immunotherapy for the treatment of glioblastoma.
    Tivnan A; Heilinger T; Lavelle EC; Prehn JH
    J Neurooncol; 2017 Jan; 131(1):1-9. PubMed ID: 27743144
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanotechnology to augment immunotherapy for the treatment of glioblastoma multiforme.
    Ung N; Yang I
    J Neurooncol; 2015 Jul; 123(3):473-81. PubMed ID: 26070553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cold Atmospheric Plasma as an Adjunct to Immunotherapy for Glioblastoma Multiforme.
    Almeida ND; Klein AL; Hogan EA; Terhaar SJ; Kedda J; Uppal P; Sack K; Keidar M; Sherman JH
    World Neurosurg; 2019 Oct; 130():369-376. PubMed ID: 31284051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The role of checkpoints in the treatment of GBM.
    Kim JE; Lim M
    J Neurooncol; 2015 Jul; 123(3):413-23. PubMed ID: 25749875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current Immunotherapies for Glioblastoma Multiforme.
    Huang B; Li X; Li Y; Zhang J; Zong Z; Zhang H
    Front Immunol; 2020; 11():603911. PubMed ID: 33767690
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunological analysis of phase II glioblastoma dendritic cell vaccine (Audencel) trial: immune system characteristics influence outcome and Audencel up-regulates Th1-related immunovariables.
    Erhart F; Buchroithner J; Reitermaier R; Fischhuber K; Klingenbrunner S; Sloma I; Hibsh D; Kozol R; Efroni S; Ricken G; Wöhrer A; Haberler C; Hainfellner J; Krumpl G; Felzmann T; Dohnal AM; Marosi C; Visus C
    Acta Neuropathol Commun; 2018 Dec; 6(1):135. PubMed ID: 30518425
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunomodulation for glioblastoma.
    Reardon DA; Wen PY; Wucherpfennig KW; Sampson JH
    Curr Opin Neurol; 2017 Jun; 30(3):361-369. PubMed ID: 28368867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Engineering challenges for brain tumor immunotherapy.
    Lyon JG; Mokarram N; Saxena T; Carroll SL; Bellamkonda RV
    Adv Drug Deliv Rev; 2017 May; 114():19-32. PubMed ID: 28625831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Glioblastoma Immune Landscape and the Potential of New Immunotherapies.
    Daubon T; Hemadou A; Romero Garmendia I; Saleh M
    Front Immunol; 2020; 11():585616. PubMed ID: 33154756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dendritic Cell-Based Immunotherapy Treatment for Glioblastoma Multiforme.
    Yang L; Guo G; Niu XY; Liu J
    Biomed Res Int; 2015; 2015():717530. PubMed ID: 26167495
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Immunotherapy in brain tumors].
    De Carli E; Delion M; Rousseau A
    Ann Pathol; 2017 Feb; 37(1):117-126. PubMed ID: 28111040
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel mechanisms and approaches in immunotherapy for brain tumors.
    Finocchiaro G; Pellegatta S
    Discov Med; 2015; 20(108):7-15. PubMed ID: 26321082
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunological challenges and opportunities in glioblastoma multiforme: A comprehensive view from immune system lens.
    Bhardwaj JS; Paliwal S; Singhvi G; Taliyan R
    Life Sci; 2024 Nov; 357():123089. PubMed ID: 39362586
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 28.